<p>Biodesix, Inc.（納斯達克代碼：BDSX - 獲取免費報告）的股票在目前覆蓋該股票的六家評級公司中獲得了 “適度買入” 的平均推薦，Marketbeat.com 報道。一位分析師給予該股票賣出評級，一位給予持有評級，四位則對該公司給予買入評級。在過去一年中，給予該股票評級的分析師的平均十二個月目標價為 32.50 美元。</p>
<p>多家券商最近對 BDSX 發佈了報告。華爾街禪在 11 月 8 日（星期六）的一份研究報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的一份研究報告中重申了對 Biodesix 股票的 “賣出（e+）” 評級。最後，Canaccord Genuity Group 在 9 月 19 日（星期五）的一份研究報告中設定了 Biodesix 股票的 20.00 美元目標價，並給予該公司 “買入” 評級。</p>
<p><strong>獲取我們對 Biodesix 的最新股票分析</strong></p>
<h2>Biodesix 股票表現</h2>
<p>Biodesix 股票在星期四開盤價為 7.87 美元。Biodesix 的 12 個月低點為 3.44 美元，12 個月高點為 32.20 美元。該公司的流動比率為 1.84，速動比率為 1.84，債務與股本比率為 41.11。該公司的 50 日簡單移動平均線為 7.34 美元，200 日簡單移動平均線為 7.14 美元。該公司的市值為 6265 萬美元，市盈率為-1.42，貝塔值為 0.98。</p>
<p>Biodesix（納斯達克代碼：BDSX - 獲取免費報告）在 11 月 3 日（星期一）最後發佈了其財報。該公司報告本季度每股收益（EPS）為（1.16 美元），超出分析師共識預期的（1.60 美元）0.44 美元。該季度的營業收入為 2177 萬美元，而共識預期為 2098 萬美元。Biodesix 的股本回報率為-504.41%，淨利潤率為-49.31%。Biodesix 已設定其 2025 財年的指導目標為每股收益。賣方分析師預測 Biodesix 本年度將發佈-0.35 的每股收益。</p>
<h2>內部交易活動</h2>
<p>在相關消息中，董事傑克·W·舒勒在 9 月 19 日（星期五）以每股平均價格 7.04 美元購買了 142,045 股公司的股票，總交易額為 999,996.80 美元。交易完成後，該董事直接持有公司 1,380,745 股股票，估值約為 9,720,444.80 美元。此次交易使其持股增加了 11.47%。該交易已在向美國證券交易委員會（SEC）提交的文件中披露，文件可通過此超鏈接訪問。在上個季度，內部人士購買了 334,836 股公司股票，價值 2,611,362 美元，並出售了 300 股，價值 2,286 美元。目前，30.10% 的股票由公司內部人士持有。</p>
<h2>Biodesix 的機構交易</h2>
<p>多家對沖基金和其他機構投資者最近對該股票的持倉進行了調整。Millennium Management LLC 在第三季度購買了 Biodesix 的新股份，價值約為 113,000 美元。Oracle Investment Management Inc. 在第三季度購買了 Biodesix 股票的新股份，價值約為 113,000 美元。XTX Topco Ltd 在第一季度購買了 Biodesix 股票的新股份，價值約為 64,000 美元。Blair William &amp; Co. IL 在第一季度將其在 Biodesix 股票中的持倉增加了 33.3%。Blair William &amp; Co. IL 目前持有 124,100 股公司股票，價值 78,000 美元，此前在該期間內又購買了 31,000 股。最後，Monashee Investment Management LLC 在第一季度將其在 Biodesix 股票中的持倉增加了 15.7%。Monashee Investment Management LLC 目前持有 4,050,000 股公司股票，價值 2,532,000 美元，此前在該期間內又購買了 549,121 股。目前，20.96% 的股票由機構投資者持有。</p>
<h2>Biodesix 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Biodesix, Inc. 在美國作為一家數據驅動的診斷解決方案公司運營。該公司提供基於血液的肺部測試，包括 Nodify XL2 和 Nodify CDT 測試，統稱為 Nodify 肺結節風險評估測試策略，以評估肺癌風險並幫助識別適當的治療路徑，並幫助醫生重新分類可疑肺結節患者的惡性風險。</p>
<h2>進一步閲讀</h2>
<ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>10 美元以下的最佳股票</li>
<li>為什麼黃金如此熱愛特朗普，就像特朗普熱愛黃金一樣</li>
<li>什麼是財報？</li>
<li>谷歌的 Gemini 3 讓博通飆升：TPU 成為焦點</li>
<li>3 個股票代碼引領了 meme 股票的復興</li>
<li>Palantir 不僅僅是在乘風 AI 熱潮——它正在指揮這一切</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
<p>在你考慮 Biodesix 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Biodesix 並不在名單上。</p>
<p>雖然 Biodesix 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

BDSX

<p>Biodesix, Inc.（納斯達克代碼：BDSX）獲得了六位分析師的 “適度買入” 推薦，其中一位為賣出，一位為持有，四位為買入評級。平均目標價為 32.50 美元。最近的升級包括華爾街 Zen 將評級從 “賣出” 調整為 “持有”。該股票開盤價為 7.87 美元，12 個月的價格區間為 3.44 美元至 32.20 美元。內部人士 Jack W. Schuler 增加了 11.47% 的持股比例。機構投資者持有該股票的 20.96%</p>

<p>Shares of Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) have earned an average recommendation of &#34;Moderate Buy&#34; from the six ratings firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $32.50.</p>
<div class="lb-trans"><p>Biodesix, Inc.（納斯達克代碼：BDSX - 獲取免費報告）的股票在目前覆蓋該股票的六家評級公司中獲得了 “適度買入” 的平均推薦，Marketbeat.com 報道。一位分析師給予該股票賣出評級，一位給予持有評級，四位則對該公司給予買入評級。在過去一年中，給予該股票評級的分析師的平均十二個月目標價為 32.50 美元。</p>
</div><p>A number of brokerages recently issued reports on BDSX. Wall Street Zen upgraded Biodesix from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research note on Saturday, November 8th. Weiss Ratings reiterated a &#34;sell (e+)&#34; rating on shares of Biodesix in a research note on Wednesday, October 8th. Finally, Canaccord Genuity Group set a $20.00 price target on shares of Biodesix and gave the company a &#34;buy&#34; rating in a research note on Friday, September 19th.</p>
<div class="lb-trans"><p>多家券商最近對 BDSX 發佈了報告。華爾街禪在 11 月 8 日（星期六）的一份研究報告中將 Biodesix 的評級從 “賣出” 上調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的一份研究報告中重申了對 Biodesix 股票的 “賣出（e+）” 評級。最後，Canaccord Genuity Group 在 9 月 19 日（星期五）的一份研究報告中設定了 Biodesix 股票的 20.00 美元目標價，並給予該公司 “買入” 評級。</p>
</div><p><strong>Get Our Latest Stock Analysis on Biodesix</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Biodesix 的最新股票分析</strong></p>
</div><h2>Biodesix Price Performance</h2>
<div class="lb-trans"><h2>Biodesix 股票表現</h2>
</div><p>Biodesix stock opened at $7.87 on Thursday. Biodesix has a 12 month low of $3.44 and a 12 month high of $32.20. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of 41.11. The business's 50 day simple moving average is $7.34 and its 200 day simple moving average is $7.14. The company has a market cap of $62.65 million, a price-to-earnings ratio of -1.42 and a beta of 0.98.</p>
<div class="lb-trans"><p>Biodesix 股票在星期四開盤價為 7.87 美元。Biodesix 的 12 個月低點為 3.44 美元，12 個月高點為 32.20 美元。該公司的流動比率為 1.84，速動比率為 1.84，債務與股本比率為 41.11。該公司的 50 日簡單移動平均線為 7.34 美元，200 日簡單移動平均線為 7.14 美元。該公司的市值為 6265 萬美元，市盈率為-1.42，貝塔值為 0.98。</p>
</div><p>Biodesix (NASDAQ:BDSX - Get Free Report) last released its earnings results on Monday, November 3rd. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.60) by $0.44. The business had revenue of $21.77 million during the quarter, compared to the consensus estimate of $20.98 million. Biodesix had a negative return on equity of 504.41% and a negative net margin of 49.31%. Biodesix has set its FY 2025 guidance at EPS. Sell-side analysts forecast that Biodesix will post -0.35 EPS for the current year.</p>
<div class="lb-trans"><p>Biodesix（納斯達克代碼：BDSX - 獲取免費報告）在 11 月 3 日（星期一）最後發佈了其財報。該公司報告本季度每股收益（EPS）為（1.16 美元），超出分析師共識預期的（1.60 美元）0.44 美元。該季度的營業收入為 2177 萬美元，而共識預期為 2098 萬美元。Biodesix 的股本回報率為-504.41%，淨利潤率為-49.31%。Biodesix 已設定其 2025 財年的指導目標為每股收益。賣方分析師預測 Biodesix 本年度將發佈-0.35 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部交易活動</h2>
</div><p>In related news, Director Jack W. Schuler bought 142,045 shares of the company's stock in a transaction on Friday, September 19th. The shares were purchased at an average price of $7.04 per share, for a total transaction of $999,996.80. Following the completion of the transaction, the director directly owned 1,380,745 shares in the company, valued at approximately $9,720,444.80. The trade was a 11.47% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last quarter, insiders acquired 334,836 shares of company stock worth $2,611,362 and sold 300 shares worth $2,286. 30.10% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在相關消息中，董事傑克·W·舒勒在 9 月 19 日（星期五）以每股平均價格 7.04 美元購買了 142,045 股公司的股票，總交易額為 999,996.80 美元。交易完成後，該董事直接持有公司 1,380,745 股股票，估值約為 9,720,444.80 美元。此次交易使其持股增加了 11.47%。該交易已在向美國證券交易委員會（SEC）提交的文件中披露，文件可通過此超鏈接訪問。在上個季度，內部人士購買了 334,836 股公司股票，價值 2,611,362 美元，並出售了 300 股，價值 2,286 美元。目前，30.10% 的股票由公司內部人士持有。</p>
</div><h2>Institutional Trading of Biodesix</h2>
<div class="lb-trans"><h2>Biodesix 的機構交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Millennium Management LLC purchased a new stake in Biodesix during the 3rd quarter worth about $113,000. Oracle Investment Management Inc. bought a new stake in shares of Biodesix during the third quarter valued at about $113,000. XTX Topco Ltd purchased a new stake in shares of Biodesix in the first quarter worth about $64,000. Blair William &amp; Co. IL boosted its position in shares of Biodesix by 33.3% in the first quarter. Blair William &amp; Co. IL now owns 124,100 shares of the company's stock valued at $78,000 after acquiring an additional 31,000 shares during the period. Finally, Monashee Investment Management LLC boosted its position in shares of Biodesix by 15.7% in the first quarter. Monashee Investment Management LLC now owns 4,050,000 shares of the company's stock valued at $2,532,000 after acquiring an additional 549,121 shares during the period. 20.96% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>多家對沖基金和其他機構投資者最近對該股票的持倉進行了調整。Millennium Management LLC 在第三季度購買了 Biodesix 的新股份，價值約為 113,000 美元。Oracle Investment Management Inc. 在第三季度購買了 Biodesix 股票的新股份，價值約為 113,000 美元。XTX Topco Ltd 在第一季度購買了 Biodesix 股票的新股份，價值約為 64,000 美元。Blair William &amp; Co. IL 在第一季度將其在 Biodesix 股票中的持倉增加了 33.3%。Blair William &amp; Co. IL 目前持有 124,100 股公司股票，價值 78,000 美元，此前在該期間內又購買了 31,000 股。最後，Monashee Investment Management LLC 在第一季度將其在 Biodesix 股票中的持倉增加了 15.7%。Monashee Investment Management LLC 目前持有 4,050,000 股公司股票，價值 2,532,000 美元，此前在該期間內又購買了 549,121 股。目前，20.96% 的股票由機構投資者持有。</p>
</div><h2>Biodesix Company Profile</h2>
<div class="lb-trans"><h2>Biodesix 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Biodesix, Inc operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules.</p>
<div class="lb-trans"><p>Biodesix, Inc. 在美國作為一家數據驅動的診斷解決方案公司運營。該公司提供基於血液的肺部測試，包括 Nodify XL2 和 Nodify CDT 測試，統稱為 Nodify 肺結節風險評估測試策略，以評估肺癌風險並幫助識別適當的治療路徑，並幫助醫生重新分類可疑肺結節患者的惡性風險。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>進一步閲讀</h2>
</div><ul>
<li>Five stocks we like better than Biodesix</li>
<li>Best Stocks Under $10.00</li>
<li>Why Gold Loves Trump as Much as Trump Loves Gold</li>
<li>What Are Earnings Reports?</li>
<li>Google's Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Biodesix 更好</li>
<li>10 美元以下的最佳股票</li>
<li>為什麼黃金如此熱愛特朗普，就像特朗普熱愛黃金一樣</li>
<li>什麼是財報？</li>
<li>谷歌的 Gemini 3 讓博通飆升：TPU 成為焦點</li>
<li>3 個股票代碼引領了 meme 股票的復興</li>
<li>Palantir 不僅僅是在乘風 AI 熱潮——它正在指揮這一切</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkRTWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=BDSX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Biodesix Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Biodesix 嗎？</h2>
</div><p>Before you consider Biodesix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Biodesix 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biodesix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻股票，頂級分析師正在悄悄地向客户推薦在更廣泛的市場注意到之前立即購買……而 Biodesix 並不在名單上。</p>
</div><p>While Biodesix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Biodesix 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Biodesix 公司（NASDAQ:BDSX）被分析師給予 “適度買入” 的平均評級